Search clinical trials for: NNC0480-0389

Total 97 results

Novo Nordisk A/S

Completed

A Research Study Looking at How Well a Combination of the Medicines Semaglutide and NNC0480-0389 Works in People With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Japan, Hungary, Poland, Russian Federation, Bulgaria, Serbia, Greece, Denmark
Novo Nordisk A/S

Completed

A Research Study of How the Medicine NNC0480-0389 Taken With Semaglutide Works in the Body of Healthy Japanese Men

Healthy Volunteers Type 2 Diabetes

Japan
Novo Nordisk A/S

Completed

First Research Study to Look at How Two Medicines, NNC0480-0389 and Semaglutide, Work Together in Healthy People, in People With High Body Weight and in People With Diabetes

Obesity | Diabetes Mellitus, Type 2 | Overweight | Healthy Volunteers

Netherlands
Novo Nordisk A/S

Completed

A Research Study Looking Into Blood Levels of the Medicine NNC0480-0389 in Participants With Reduced Kidney Function Compared to Participants With Normal Kidney Function

Diabetes Mellitus, Type 2

Germany
Novo Nordisk A/S

Completed

A Research Study of How the Medicine NNC0480-0389 Taken With Semaglutide Works in the Body of Healthy Chinese Men

Diabetes Mellitus, Type 2

China
Novo Nordisk A/S

Completed

A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People

Diabetes Mellitus, Type 2

Germany
Novo Nordisk A/S

Completed

A Research Study Looking Into the Effect of Semaglutide and NNC0480 0389 on Blood Levels of a Birth Control Pill in Woman After Menopause

Diabetes Mellitus, Type 2

Germany
Novo Nordisk A/S

Completed

A Research Study on How NNC0487-0111 Works in People With Overweight or Obesity

Obesity

United States
Novo Nordisk A/S

Recruiting

A Research Study to See How a New Medicine (NNC0487-0111) Works in People With Overweight or Obesity When Injected Under the Skin

Obesity | Overweight

United States
Novo Nordisk A/S

Completed

A Research Study of How a New Medicine Called Amycretin, Given as Tablets, Works in Japanese Men With Obesity

Obesity

Japan
Novo Nordisk A/S

Completed

A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation II

Healthy Volunteers; High Cholesterol

United States
Novo Nordisk A/S

Recruiting

A First Human Dose Study Investigating Safety and Concentration of Study Medicine in the Blood Following Once Daily Oral Dosing of NNC0560-0004 in Healthy Adults.

Healthy Volunteers - Liver Diseases

United Kingdom
Novo Nordisk A/S

Completed

A Research Study Investigating How NNC0385-0434 is Tolerated in People With or Without High Cholesterol Levels

Healthy Volunteers | Hypercholesterolaemia

United Kingdom
Novo Nordisk A/S

Completed

A Study to Look at How Insulin NNC0471-0119 Works in the Body in People With Type 1 Diabetes When Injected by Insulin Pump

Diabetes Mellitus, Type 1

Austria
Novo Nordisk A/S

Completed

A Research Study Looking at New Protein-based Tablets in Healthy Male Participants

Type 2 Diabetes | Healthy Volunteers | High Blood Cholesterol Levels

Germany, Canada
Novo Nordisk A/S

Completed

A Research Study Looking at the Effect of Food Intake on How the Medicine NN0385-0434 Behaves in the Body of Healthy Participants

Healthy Volunteers | Elevated Cholesterol | Established Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD Risk

Germany
Genentech, Inc.

Completed

Evaluating the Safety and Tolerability of GDC-0349 in Patients With Locally Advanced or Metastatic Solid Tumors or Non Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma, Solid Tumor

Canada, United States
Novo Nordisk A/S

Recruiting

A Study to Look at Safety and Tolerability of NNC0582-0001, How it is Transported Throughout the Body and How it Works in Healthy Adults

Healthy Volunteers

Austria
Novo Nordisk A/S

Completed

A Research Study Looking at How the Medicine NNC0385-0434 Works in the Body of Healthy Japanese Men

Healthy Volunteers | Atherosclerotic Cardiovascular Disease

Japan
Novo Nordisk A/S

Recruiting

A Study to Look at How Safe a New Medicine (NNC0491-6075) is in Healthy People and in Participants With High Levels of Fat in the Blood

Healthy Volunteers | Dyslipidaemia

United States
Novo Nordisk A/S

Completed

A Research Study to Look at How Insulin 287 and Semaglutide Work in the Body of People With Type 2 Diabetes When Taken Alone or Together

Diabetes Mellitus, Type 2

Germany
Novo Nordisk A/S

Completed

A Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0215-0384 Administered to Subjects With Moderate to Severe Rheumatoid Arthritis

Inflammation | Rheumatoid Arthritis

Germany, Russian Federation, Poland, Hungary
Novo Nordisk A/S

Recruiting

A Research Study of a New Medicine (NNC0650-0013) in Healthy Men

Healthy Participants

Germany
Novo Nordisk A/S

Terminated

A Research Study Looking Into Levels of the Medicine NNC0385-0434 in the Body and How Well it is Tolerated in Participants With Impaired Kidney Function Compared to Participants With Normal Kidney Function

Chronic Kidney Disease

Germany
Abbott

Terminated

A Safety and Tolerability Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)

Attention-Deficit/Hyperactivity Disorder

United States
Novo Nordisk A/S

Completed

A Study to Look at How Safe NNC0472-0147 is in Healthy People and in People With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Healthy Volunteers

Germany
AbbVie (prior sponsor, Abbott)

Completed

A Safety and Tolerability Study of ABT-089 in Adults With Attention Deficit-Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder

United States
Abbott

Terminated

A Study of the Long-term Safety of ABT-089 for Subjects With Mild-to-moderate Alzheimer's Disease Who Participated in the M06-876 Study

Alzheimer's Disease

United States
Abbott

Terminated

A Study of the Safety and Efficacy of Multiple Doses of ABT-089 in Subjects With Alzheimer's Disease

Alzheimer's Disease

United States
AbbVie (prior sponsor, Abbott)

Completed

Safety and Tolerability Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)

Attention-Deficit/Hyperactivity Disorder

United States
Abbott

Completed

A Dose-Ranging, Cross-over Study of the Safety and Efficacy of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Attention-Deficit/Hyperactivity Disorder

United States
Novo Nordisk A/S

Completed

A Research Study Looking at How NNC0385-0434 Tablets Work to Lower Blood Cholesterol in People With Heart Disease or a High Risk of Heart Disease

Atherosclerotic Cardiovascular Disease

Germany, Poland, United States, Netherlands, Japan, Greece, Belgium
Novo Nordisk A/S

Recruiting

First Human Dose Trial for a New Medication to Potentially Treat Liver Diseases

Healthy Volunteers

United Kingdom
Shandong Luoxin Pharmaceutical Group Stock Co.,...

Completed

A Phase I Study of LX-039 Tablets

Advanced Breast Cancer

China
Novo Nordisk A/S

Withdrawn

Examination of the Safety and Tolerability of NNC 0070-0002-0349 in Overweight/Obese Volunteers

Obesity | Metabolism and Nutrition Disorder
National Center of Neurology and Psychiatry, Japan
Nippon Shinyaku Co., Ltd.

Completed

Exploratory Study of NS-089/NCNP-02 in DMD

Duchenne Muscular Dystrophy

Japan
Sichuan Baili Pharmaceutical Co., Ltd.
SystImmune Inc.; Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Recruiting

A Study of GNC-038 Injection in Patients With Relapsed or Refractory NK/ T-cell Lymphoma, AITL, and Other NHL

Non-Hodgkin Lymphoma | NK/T Cell Lymphoma | Vascular Immunomother T Cell Lymphoma

China
AbbVie (prior sponsor, Abbott)

Completed

Long Term Safety and Tolerability Study of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Attention-Deficit/Hyperactivity Disorder

United States
Biocad

Completed

The BCD-089 (aIL6R) in Patients With Active Rheumatoid Arthritis (AURORA)

Seropositive RA

Russian Federation, Belarus
Sun Pharma Advanced Research Company Limited

Completed

Study of Doxorubicin in Patients With Metastatic Breast Cancer/Advanced Ovarian Cancer

Breast Cancer and Ovarian Cancer
Affibody
Parexel

Terminated

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of ABY-039

Healthy Volunteers

United Kingdom
AbbVie (prior sponsor, Abbott)

Completed

Safety, Tolerability and Efficacy Study of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Attention-Deficit/Hyperactivity Disorder

United States
Sichuan Baili Pharmaceutical Co., Ltd.
SystImmune Inc.

Recruiting

A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL)

Diffuse Large B-cell Lymphoma

China
Sichuan Baili Pharmaceutical Co., Ltd.
SystImmune Inc.

Recruiting

A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors

Solid Tumor | Recurrent Glioma

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

Safety and Efficacy of IBI389 Single Agent, and in Combination With Sintilimab, in Patients With Advanced Malignancies

Advanced Solid Tumors

China
Sichuan Baili Pharmaceutical Co., Ltd.
SystImmune Inc.

Recruiting

Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | Non Hodgkin Lymphoma

China
Nippon Shinyaku Co., Ltd.

Active, not recruiting

Extension Study of NS-089/NCNP-02 in DMD

Duchenne Muscular Dystrophy (DMD)

Japan
ADARx Pharmaceuticals, Inc.
ADARx Australia Pty Ltd

Recruiting

Safety, Tolerability, PK and PD of ADX-038 in HV and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients (PNH)

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Australia
Chr Hansen

Completed

Efficacy of a Probiotic Strain on Level of Markers of Inflammation in an Elderly Population

Inflammation

Ireland
AO GENERIUM

Completed

Safety and Pharmacokinetics of GNR-038 in Healthy Volunteers

Hereditary Angioedema

Russian Federation

3

Subscribe